Log in | Register

Limiting consumption in tuberculosis: current concepts in anti-tuberculosis treatment in the critically ill patient

Mervyn Mer| Alimuddin Zumla| Martin W. Dünser
What's New in Intensive Care
Volume 44, Issue 12 / December , 2018

Pages 2229 - 2231

No abstract available.

References

  1. World Health Organization (2017) Tuberculosis factsheet. http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 22 Oct 2017
  2. Otu A, Hashmi M, Mukhtar AM, Kwizera A, Tiberi S, Bacrae B, Zumla A, Dünser MW, Mer M (2018) The critically ill patient with tuberculosis in intensive care: clinical presentations, management and infection control. J Crit Care 45:184–196
    • View reference on publisher's website
  3. Zumla A, Raviglione M, Hafner R, von Reyn F (2013) Tuberculosis. N Engl J Med 368:745–755
    • View reference on publisher's website
  4. Kethireddy S, Light RB, Mirzanejad Y, Maki D, Arabi Y, Lapinsky S, Sion D, Kumar A, Parrillo JE, Kumar A, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Group (2013) Mycobacterium tuberculosis septic shock. Chest 144:474–482
    • View reference on publisher's website
  5. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N (2014) Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009593.pub3
    • View reference on publisher's website
  6. World Health Organization (2017) Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). April 2017, WHO/HTM/TB/2017.05
  7. World Health Organization (2016) WHO treatment guidelines for drug-resistant tuberculosis (2016 update). October 2016, WHO/HTM/TB/2016.04
  8. Koegelenberg CF, Nortje A, Lalla U, Enslin A, Irusen EM, Rosenkranz B, Seifart HI, Bolliger CT (2013) The pharmacokinetics of enteral anti-TB drugs in patients requiring intensive care. S Afr Med J 103:394–398
    • View reference on publisher's website
  9. Mer M, Lipman (2015) Antibiotic administration in the critically ill—in need of intensive care! S Afr Med J 105:357–359
    • View reference on publisher's website
  10. Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, Nuermberger E, Gumbo T (2016) Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 63(Suppl 3):S63–S74
    • View reference on publisher's website
  11. Tseng YT, Chuang YC, Shu CC, Hung CC, Hsu CF, Wang JY (2012) Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia. Crit Care 16:R207
    • View reference on publisher's website
  12. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R (2013) Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 13:27–35
    • View reference on publisher's website
  13. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtfaya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M, PanACEA consortium (2017) High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomized controlled trial. Lancet Infect Dis 17:39–49
    • View reference on publisher's website
  14. Heemskerk AD, Bang ND, Mai NT, Chau TT, Phu NH, Loc PP, Chau NV, Hien TT, Dung NH, Lan NT, Lan NH, Lan NN, Phong Ie T, Vien NN, Hien NQ, Yen NT, Ha DT, Day JN, Caws M, Merson L, Thinh TT, Wolbers M, Thwaites GE, Farrar JJ (2016) Intensified anti-TB therapy in adults with tuberculous meningitis. N Engl J Med 374:124–134
    • View reference on publisher's website
  15. Choi R, Jeong BH, Koh WJ, Lee SY (2017) Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med 37:97–107
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement